Healthcare Sector Overview: List of Healthcare Stocks in India

The Covid 19 pandemic has made us realise the importance of good health. Timely and effective diagnostic tests have helped us beat Covid with limited damage. Healthcare sector becomes very important for any nation in this pandemic. If we look at the performance of the overall healthcare industry in the past 5 years then, the S&P BSE Healthcare Index has offered decent returns of 65.63% as on 2nd May 2022. Moreover, during the Covid 19 pandemic, the healthcare index offered an absolute return of 90% from March 2020 to March 2022. However, in the past year, the tables have turned.  The S&P BSE Healthcare Index has offered only a mere return of 2.78% whereas Nifty has offered a return of 16.87% during the same time as on 2nd May 2022. Not just that, the stocks of the sector have also taken a hit. Dr Lal PathLabs Ltd is down by 27.58% in the past one year (as of 2nd May 2022). Another renowned healthcare stock, Metropolis Healthcare Ltd is down by 20.39% during the same duration. Not just that, there are many other healthcare stocks which are currently declining. So, what might be the reason behind this? To understand it better, you need to first understand the healthcare industry better. So, let’s begin. About the Healthcare Sector The healthcare sector is vast. It includes:
  1. Diagnostic
The diagnostic sector is a major part of the healthcare industry. The diagnostic sector plays the role of an information intermediary. The role of the diagnostic company is to offer useful information for accurate diagnosis and treatment of diseases. So, whenever you visit a clinic for a blood test or magnetic resonance imaging (MRI) then that clinic is said to be a diagnostic center. Now, the diagnostic industry is widely spread. There are unorganised players (47%), hospital-based labs (37%) and organized players (~16%). As multiple players are offering the same test at different prices. In such a situation, patients often prefer to go to a clinic which gets the test done at a comparatively cheaper price. Hence, the challenge that the diagnostic players face is the pricing pressure. So, players often focus on acquiring more patients so that their profit margin increases contributing to the increase in total revenue.
  1. Medical devices, equipment, and hospital supplies manufacturers
These players focus on manufacturing products for the healthcare sector. They make surgical instruments, dental equipments, laser machine and a lot more. They also manufacture hospital beds and other equipment required in the hospital.
  1. Medical insurance players
Medical insurance players provide medical insurance or similar services to their patients. This sector includes players like health maintenance organizations (HMOs), companies which offer medicare services, healthcare consultants and healthcare staff recruitment agencies.
  1. Pharmaceutical segment
The pharmaceutical segment is an important part of the healthcare industry. This sector consists of players that produce over the counter (OTC) drugs, prescription drugs, biopharmaceutical drugs and generic drugs.

List of Healthcare Stocks Listed in India

Name Current Price Market Capitalization
Sun Pharmaceutical Industries 872 2,09,102
Divi's Laboratories 4,270 1,13,347
Cipla Limited 924 74,546
Dr. Reddy's Laboratories 3,919 65,222
Apollo Hospitals 3820 54940.36
Torrent Pharma 2,629 44,486
Piramal Enterprises Limited 1,833 43,747
Biocon Limited 331 39,740
Alkem Laboratories 3,014 36,037
Abbott India Ltd. 16,765 35,625
Max Healthcare 364.45 35338.33
Aurobindo Pharma Limited 566 33,167
Lupin Limited 699 31,779
Laurus Labs Ltd. 544 29,219
Dr Lal Pathlabs 2401.8 20017.82
Fortis Healthcare 243 18,345.48
Alembic Pharmaceuticals 739 14,532
Narayana Hrudayalay 667.6 13,643.13
Glenmark Pharma Limited 398 11,230
Metropolis Health. 2,113.00 10,813.22
Krishna Institu. 1272.2 10182.3
Aster DM Health. 184.4 9218.28
Poly Medicure 832.7 7987.49
Vijaya Diagnost. 410.95 4191.77
Thyrocare Tech. 746.85 3,951.09
Health.Global 274.75 3820.05
Kovai Medical 1561.95 1704.07
Krsnaa Diagnostics 532 1,670.35
Kovai Medical Center 1,455.95 1,593.14
Shalby 108.25 1,169.21
KMC Speciality Hosp 600 978.51
Indrapr.Medical 62 570.6
Artemis Medicare 40.1 531.43
Innovexia Life Sciences Pvt. Ltd. 435 446
Prevest Denpro 360 432.11
Kaya 321.8 420.4
Dr Agarwals Eye Hsp 779 366.13
Tejnaksh Healthcare 142.65 144.89
Jeevan Scienti. 92.65 141.78
Global Longlife 128.6 135.03
Aashka Hospitals 45.6 106.7
Lotus Eye Hospital 50.9 105.85
Fortis MalarHospital 52.5 98.39
Scandent Imaging 18.95 60.83
Opto Circuits 2 60.13
Deccan Healthcar 38.15 59.96
Aspira Pathlab&Diagn 54.05 55.63
Nidan Laborator. 38.3 53.24
Adeshwar Meditex 28.25 40.77
Gian Lifecare 29.95 30.97
Medinova Diagnostic 28.5 28.45
Transgene Biotek 3.74 28.34
Centenial Surgic 60.65 22.14
NG Industries 64.25 21.53
Choksi Lab 28.1 19.57
Chennai Meena 23 17.18
Dr Lalchandani Labs 34.4 14.91
Soni Medicare 26.3 11.22
Looks Health Service 10.35 10.87
Shree Pacetronix 21.3 7.67
Indo-Global Enter. 10.08 6.42
DhanvantriJeevan Rek 13.5 5.53
Constronics Infra 5.55 4
Dolphin Medical Serv 2.03 3.07

Let’s Take a Look at A Few Stocks from The Healthcare Sector

Apollo hospitals

Apollo Hospitals owns the largest pharmacy chain in India. Not just that the hospital has also emerged as Asia’s foremost integrated healthcare services provider as it has a solid presence in the healthcare sector. This includes hospitals, pharmacies, primary care & diagnostic clinics and several retail health models. The company generates majority of its revenue from its healthcare business (53%). Its pharmacy business, Apollo pharmacy helps the company generate 41% revenues. Its health and lifestyle business generates 6% revenues. The hospital has 4,118 outlets across 20 states and 4 union territories. The consolidated revenues of the company grew at a CAGR of 17% since 2013. The healthcare services revenue grew at a CAGR of 12%. Source: Investor presentation of Apollo hospitals Quick overview of Apollo Hospitals
Market Cap (Cr): Rs. 55,178 Cr. Face Value: Rs. 5 EPS: Rs. 78.8
Book Value: Rs. 369 Roce (%): 8.44 Debt to Equity: 0.80
Stock PE: 63 ROE (%): 3.79 Dividend Yield (%): 0.08
 Promoter’s Holdings (%): 29.33 Total Debt (Cr): Rs. 4,236
*Data as on 6th May 2022

Max healthcare

Max healthcare is the second largest hospital chain in the healthcare segment. It has excelled in offering services of oncology, neurosciences, cardiac sciences, orthopaedics, renal sciences and a lot more. Their chain of hospitals has a total bed capacity of more than 3,400 beds out of which 85% of beds are available in metro cities. The revenue of the company has also increased by 13% CAGR in the last three years (as on 24th February 2022). Recently the company has also acquired a 37% stake in Eqova healthcare which has a potential of adding 400+ beds in East Delhi. Source: Investor presentation of Max healthcare Quick overview of Max healthcare
Market Cap (Cr): Rs. 35,110 Face Value: Rs. 10 EPS: Rs. 2.81
Book Value: Rs. 63.2 Roce (%): 3.55 Debt to Equity: 0.07
Stock PE: 129 ROE (%): 1.45 Dividend Yield (%): 0
 Promoter’s Holdings (%): 50.64 Total Debt (Cr): Rs. 445
*Data as on 6th May 2022

Lal Path labs

Dr Lal Path labs is a renowned name and India’s leading consumer healthcare brand in the diagnostic sector. The company has an integrated nationwide network where they offer a broad range of diagnostic and healthcare-related tests and services. The company has 216 laboratories, 3,095 patient service centres and around 7,000 pick-up units available across India. However, the company has dominated presence in the Northern parts of the country. If we look at the geographical breakup then, Delhi NCR is the dominant market for the company which has a market share of around 37%. In the financial year 2021, the consolidated income of the company increased to Rs. 16,325.99 million compared to Rs. 13,854.02 million in the previous year. The revenues of the company have increased at a CAGR of 15% since 2019. Also, the profit before tax has increased at a CAGR of 15%. Profit after tax has increased at a CAGR of 22%. *Source: Annual report of 2021 Quick overview of Dr. Lal Pathlabs
Market Cap (Cr): Rs. 19,801 Face Value: Rs. 10 EPS: Rs. 44
Book Value: Rs. 165 Roce (%): 35.4 Debt to Equity: 0.03
Stock PE: 53.9 ROE (%): 25.1 Dividend Yield (%):0.83
 Promoter’s Holdings (%): 55.2 Total Debt (Cr): Rs. 41.4
*Data as on 6th May 2022

Fortis Healthcare

Fortis Healthcare is a leading integrated healthcare service provider across PAN India. The healthcare verticals of the company consist of hospitals, diagnostics and day care speciality facilities. The company had recently acquired Super Religare Laboratories (SRL). It operates its diagnostics business through its 57% owned subsidiary in SRL Limited. If we look at the financials of Fortis Healthcare then, the operating income in Q4FY2021 doubled as compared to the Q1FY2021. In Q1 the operating income was just Rs. 606 crores. Whereas, in Q4 the operating income is a whopping Rs. 1,252 cores. The earnings before interest, taxes, depreciation, and amortization (EBITDA) and Profit after tax (PAT) margins have also improved. *Source: Annual report 2021 Quick overview of Fortis Healthcare
Market Cap (Cr): Rs. 19,112 Face Value: Rs. 10 EPS: Rs. 7.02
Book Value: Rs. 81 Roce (%): 2.59 Debt to Equity: 0.25
Stock PE: 53.3 ROE (%):  -1.72 Dividend Yield (%):0
 Promoter’s Holdings (%): 31.2 Total Debt (Cr): Rs. 1,522
*Data as on 6th May 2022

Metropolis Healthcare 

Metropolis Healthcare Ltd. is another leading healthcare company dominating in the western parts of India. The revenue of the company grew by 17% in FY2021 as compared to FY2020. Profit after tax (PAT) grew by 44% in FY2021 as compared to FY2020. The average revenue per patient also increased to Rs. 1,015 which previously was Rs. 856. *Source: Annual report 2021 Quick overview of Metropolis Healthcare
Market Cap (Cr): Rs. 10,950 Face Value: Rs. 2 EPS: Rs. 46.1
Book Value: Rs. 165 Roce (%): 36.2 Debt to Equity: 0.14
Stock PE: 48.9 ROE (%): 29.7 Dividend Yield (%):0.37
 Promoter’s Holdings (%): 49.8 Total Debt (Cr): Rs. 115
*Data as on 6th May 2022

Vijaya Diagnostic

Vijaya Diagnostics Centre is a leading and the largest diagnostic services provider in Southern parts of India. It offers services like nuclear medicine, radiology, laboratory, health check-ups and medical services. They have 81 diagnostic centers and 11 laboratories across 13 cities as of June 30, 2021. More than 92% of revenue is generated from its business to customer (B2C) segment. The unique part of the company is that it follows a hub and spoke model. So, in a hub and spoke model the company will have test centers at multiple places but the laboratory will be at a different location. So, the test centers will collect the samples and send them to the laboratory at once. This will help the company increase its geographical presence while reducing its capital expenditure (Capex). Quick overview of Vijaya Diagnostic
Market Cap (Cr): Rs. 4,198 Face Value: Rs. 1 EPS: Rs. 18.6
Book Value: Rs. 41.2 Roce (%): 27.2 Debt to Equity: 0.40
Stock PE: 50 ROE (%): 26.5 Dividend Yield (%):0
 Promoter’s Holdings (%): 54.78 Total Debt (Cr): Rs. 167
*Data as on 6th May 2022 Bottom line The Covid-19 wave has been fading out and the omicron wave contribution has been significantly less. Moreover, unlock has been announced in major cities which will lead to lesser contribution towards Covid revenue. So, the companies will have to increase its non covid revenue to grow their business. But, no matter what we are never going to compromise with our health and hence the healthcare industry is forever going to be in the spotlight. To know which are the best healthcare stocks to buy, all you need to do is visit Samco’s star ratings page and check the ratings for healthcare stocks. The rating of a stock is revised daily and is calculated using more than twenty million data points. It also mentions the ratios and pros and cons of investing in the company. So, researching stocks just got easier. To invest in any of the healthcare stock, open a  Free Demat account with Samco.

Download App to know your Andekha Sach

Get the link to download the app.

Google Play Store App Store
Samco Fast Trading App

About The Author

Leave A Comment?